Ionis Pharmaceuticals Cuts Tryngolza Forecast, Stock Falls 27%
Ionis Pharmaceuticals fell 27% in a single session after cutting its Tryngolza revenue forecast, hitting a 52-week low and raising doubts about whether the drug can reverse the company's 40.7% year-ov
Ionis Pharmaceuticals Cuts Tryngolza Forecast, Stock Falls 27%
NEW YORK, November 9 —
Ionis Pharmaceuticals, Inc. (IONS) plunged 27% to a 52-week low of $30.24 Monday after cutting its Tryngolza revenue forecast.
- IONS fell 27% in a single session, closing at $30.24, a 52-week low
- With a forward P/E of -26.4x and $347mn in annual FCF burn, the stock has no earnings floor to absorb a broken commercial story
- Tryngolza net product revenue in the next quarterly filing is the only number that resets the ramp narrative
One Drug Was the Entire Revenue Recovery Plan
Ionis Pharmaceuticals (IONS) is not a company that earns money today. Trailing EPS sits at -$3.48, and the business burns $347mn in free cash flow annually. When a company operates at that level of cash consumption, the stock price is a forward bet on a commercial ramp, not a reflection of current results. Tryngolza, Ionis's commercial-stage asset, was that bet. Monday's forecast cut does not simply trim one revenue line. It breaks the thesis that justified holding a loss-making biotech at any multiple.
16.5% of the Float Was Already Betting Against the Ramp
Before Monday's session opened, 16.5% of IONS's float was sold short. That is a conviction position, not a hedge. The gap-down visible in the chart is the moment a crowded short thesis got confirmed: Tryngolza's commercial uptake is running below management's own expectations. For shareholders who bought the ramp story, the question is whether this is a one-quarter timing slip or a structural ceiling on how large Tryngolza's addressable market actually is. Any rebuttal to the short thesis needs a compelling answer to that question before the stock finds a durable floor.
A 40.7% Revenue Decline Had No Margin for Error
TTM revenue of $874mn already reflects a 40.7% YoY decline heading into this cut. That figure matters because it means Tryngolza's ramp was not being asked to accelerate a healthy base business. It was being asked to reverse a deteriorating one. A guidance reduction against that backdrop is doubly damaging: it confirms the recovery thesis is off-schedule while the existing business continues to shrink. With a forward P/E of -26.4x, the market has no earnings anchor to fall back on while waiting for the drug to ramp.
The Next Tryngolza Number Either Restores or Ends the Setup
The specific revised Tryngolza revenue target has not been disclosed in public headlines. That gap makes the next quarterly filing the most important document IONS will publish in the near term. Watch for Tryngolza net product revenue, management's ramp timeline commentary, and any revision to the full-year outlook. Run the numbers on what various Tryngolza revenue trajectories imply for the stock at current cash burn rates using a DCF calculator. If the next quarter shows meaningful acceleration, Monday's selloff looks like an overreaction to a timing miss. If it doesn't, the -40.7% revenue trend has nowhere to hide and 16.5% short interest has more room to run.
Get a full picture of IONS's pipeline and financial setup at Basis Report's IONS stock page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Ionis Pharmaceuticals shares dropped 27% after the company lowered its revenue forecast for Tryngolza, sending the stock to a 52-week low.